Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2024 | 277 | 1.580 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2017 | 79 | 1.040 |
Why?
|
| Kidney Neoplasms | 7 | 2017 | 103 | 1.010 |
Why?
|
| Urologic Neoplasms | 3 | 2021 | 13 | 0.910 |
Why?
|
| Cystectomy | 4 | 2017 | 104 | 0.890 |
Why?
|
| Urologists | 2 | 2019 | 5 | 0.730 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2020 | 13 | 0.730 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2017 | 6 | 0.640 |
Why?
|
| Biopsy | 2 | 2017 | 207 | 0.610 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2017 | 164 | 0.580 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 9 | 0.570 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 17 | 0.560 |
Why?
|
| Insurance Coverage | 1 | 2017 | 33 | 0.560 |
Why?
|
| Insurance, Health | 1 | 2017 | 51 | 0.560 |
Why?
|
| Penile Neoplasms | 1 | 2016 | 12 | 0.500 |
Why?
|
| Male | 26 | 2024 | 13510 | 0.500 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2015 | 5 | 0.500 |
Why?
|
| Neoplasm Staging | 11 | 2017 | 478 | 0.490 |
Why?
|
| Humans | 40 | 2024 | 28166 | 0.480 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2015 | 4 | 0.480 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 53 | 0.480 |
Why?
|
| Algorithms | 1 | 2017 | 433 | 0.450 |
Why?
|
| Thymus Neoplasms | 4 | 2014 | 8 | 0.450 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 144 | 0.440 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 164 | 0.440 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 298 | 0.410 |
Why?
|
| Prostate-Specific Antigen | 2 | 2024 | 53 | 0.340 |
Why?
|
| Urologic Diseases | 1 | 2010 | 6 | 0.340 |
Why?
|
| Radiation Dosage | 1 | 2010 | 54 | 0.330 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2014 | 72 | 0.320 |
Why?
|
| Prostatectomy | 1 | 2009 | 83 | 0.310 |
Why?
|
| Aged | 13 | 2024 | 5416 | 0.310 |
Why?
|
| Urology | 2 | 2019 | 30 | 0.300 |
Why?
|
| Middle Aged | 14 | 2024 | 7164 | 0.290 |
Why?
|
| Female | 19 | 2024 | 15191 | 0.280 |
Why?
|
| Germ-Line Mutation | 3 | 2016 | 32 | 0.270 |
Why?
|
| Wetlands | 1 | 2025 | 8 | 0.240 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 126 | 0.240 |
Why?
|
| Plant Roots | 1 | 2025 | 50 | 0.240 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 67 | 0.240 |
Why?
|
| Adult | 10 | 2024 | 7765 | 0.240 |
Why?
|
| Tomography, Optical Coherence | 1 | 2025 | 94 | 0.230 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2016 | 56 | 0.230 |
Why?
|
| Machine Learning | 1 | 2025 | 85 | 0.230 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2003 | 19 | 0.220 |
Why?
|
| Placenta | 1 | 2024 | 78 | 0.220 |
Why?
|
| Retrospective Studies | 9 | 2017 | 2558 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 677 | 0.220 |
Why?
|
| Smartphone | 1 | 2024 | 63 | 0.220 |
Why?
|
| Mobile Applications | 1 | 2024 | 61 | 0.220 |
Why?
|
| Sex Characteristics | 1 | 2024 | 172 | 0.210 |
Why?
|
| Lipid Metabolism | 1 | 2024 | 133 | 0.210 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 68 | 0.210 |
Why?
|
| Nephrectomy | 3 | 2014 | 47 | 0.210 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 2021 | 0.200 |
Why?
|
| Gram-Negative Bacteria | 1 | 2003 | 62 | 0.200 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 678 | 0.200 |
Why?
|
| Young Adult | 4 | 2017 | 2738 | 0.190 |
Why?
|
| Risk Factors | 5 | 2016 | 2087 | 0.180 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 4 | 0.180 |
Why?
|
| Health Planning | 1 | 2001 | 7 | 0.180 |
Why?
|
| Oncologists | 1 | 2021 | 15 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 296 | 0.180 |
Why?
|
| Smoking Prevention | 1 | 2001 | 89 | 0.170 |
Why?
|
| Minority Health | 1 | 2019 | 5 | 0.160 |
Why?
|
| Rural Health Services | 1 | 2019 | 24 | 0.160 |
Why?
|
| Child | 3 | 2015 | 2253 | 0.160 |
Why?
|
| Health Promotion | 1 | 2001 | 176 | 0.160 |
Why?
|
| Referral and Consultation | 2 | 2019 | 97 | 0.160 |
Why?
|
| Obesity | 1 | 2024 | 668 | 0.150 |
Why?
|
| Disease Progression | 2 | 2017 | 474 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 523 | 0.150 |
Why?
|
| Patient Selection | 1 | 2019 | 148 | 0.150 |
Why?
|
| Genetic Testing | 2 | 2017 | 68 | 0.150 |
Why?
|
| Prognosis | 7 | 2015 | 803 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 300 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 143 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 215 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 163 | 0.140 |
Why?
|
| Androstane-3,17-diol | 1 | 2017 | 9 | 0.140 |
Why?
|
| Anabolic Agents | 1 | 2017 | 12 | 0.140 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2017 | 21 | 0.140 |
Why?
|
| Receptors, GABA-A | 1 | 2017 | 18 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 19 | 0.140 |
Why?
|
| Research Report | 1 | 2017 | 23 | 0.140 |
Why?
|
| Checklist | 1 | 2017 | 23 | 0.140 |
Why?
|
| Mutation | 3 | 2017 | 849 | 0.140 |
Why?
|
| Leiomyomatosis | 1 | 2017 | 2 | 0.140 |
Why?
|
| Leiomyoma | 1 | 2017 | 9 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 555 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2017 | 115 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 70 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 71 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2016 | 16 | 0.130 |
Why?
|
| Genetic Counseling | 1 | 2015 | 14 | 0.120 |
Why?
|
| Ultrasonic Therapy | 1 | 2015 | 4 | 0.120 |
Why?
|
| Body Temperature | 1 | 2015 | 30 | 0.120 |
Why?
|
| Papillomaviridae | 1 | 2016 | 88 | 0.120 |
Why?
|
| Registries | 1 | 2017 | 386 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2016 | 2383 | 0.120 |
Why?
|
| Cisplatin | 1 | 2016 | 179 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 153 | 0.120 |
Why?
|
| Thalidomide | 1 | 2014 | 13 | 0.110 |
Why?
|
| Vaccination | 1 | 2016 | 183 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2017 | 241 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 122 | 0.110 |
Why?
|
| Adolescent | 3 | 2015 | 3128 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 27 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 38 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 75 | 0.110 |
Why?
|
| Oklahoma | 1 | 2017 | 1005 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 50 | 0.110 |
Why?
|
| Dyskeratosis Congenita | 1 | 2013 | 1 | 0.110 |
Why?
|
| Microcephaly | 1 | 2013 | 8 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 6 | 0.110 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 53 | 0.100 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 32 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2003 | 29 | 0.100 |
Why?
|
| Intellectual Disability | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2017 | 889 | 0.100 |
Why?
|
| DNA Helicases | 1 | 2013 | 53 | 0.100 |
Why?
|
| ABO Blood-Group System | 1 | 2012 | 7 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 247 | 0.100 |
Why?
|
| Infant | 1 | 2015 | 1014 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2015 | 1149 | 0.100 |
Why?
|
| United States | 4 | 2019 | 2151 | 0.090 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2011 | 4 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 634 | 0.090 |
Why?
|
| Malnutrition | 1 | 2011 | 31 | 0.090 |
Why?
|
| Nutritional Status | 1 | 2011 | 78 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2016 | 289 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2015 | 611 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 20 | 0.080 |
Why?
|
| Survival Rate | 4 | 2012 | 430 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 356 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 226 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 595 | 0.070 |
Why?
|
| Kidney | 1 | 2009 | 286 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 454 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 477 | 0.070 |
Why?
|
| Time Factors | 3 | 2017 | 1593 | 0.060 |
Why?
|
| Louisiana | 1 | 2025 | 7 | 0.060 |
Why?
|
| Biomass | 1 | 2025 | 86 | 0.060 |
Why?
|
| Jews | 2 | 2016 | 7 | 0.060 |
Why?
|
| Genome, Human | 2 | 2016 | 73 | 0.060 |
Why?
|
| Biological Transport, Active | 1 | 2003 | 17 | 0.050 |
Why?
|
| Lipids | 1 | 2024 | 208 | 0.050 |
Why?
|
| Tennessee | 2 | 2014 | 27 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 99 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 608 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 436 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 386 | 0.050 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 118 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 260 | 0.050 |
Why?
|
| Telemedicine | 1 | 2024 | 174 | 0.050 |
Why?
|
| Drug and Narcotic Control | 1 | 2001 | 7 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 194 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2001 | 86 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2001 | 46 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2003 | 336 | 0.040 |
Why?
|
| Research | 1 | 2001 | 92 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1191 | 0.040 |
Why?
|
| Animals | 2 | 2024 | 10416 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sample Size | 1 | 2019 | 17 | 0.040 |
Why?
|
| Informed Consent | 1 | 2019 | 24 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 242 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2013 | 1257 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2017 | 101 | 0.030 |
Why?
|
| American Cancer Society | 1 | 2017 | 4 | 0.030 |
Why?
|
| Fumarate Hydratase | 1 | 2017 | 4 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 315 | 0.030 |
Why?
|
| Smoking | 1 | 2001 | 473 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 93 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 54 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 210 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 45 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 1 | 0.030 |
Why?
|
| Thermometers | 1 | 2015 | 1 | 0.030 |
Why?
|
| Heating | 1 | 2015 | 6 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 108 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 255 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 50 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 73 | 0.030 |
Why?
|
| Neoplasms | 1 | 2024 | 818 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 134 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 237 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 283 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2015 | 18 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 104 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 128 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 217 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 134 | 0.030 |
Why?
|
| Mice | 1 | 2024 | 4655 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 457 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 247 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 806 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 125 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 6 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2013 | 21 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 40 | 0.030 |
Why?
|
| Sutures | 1 | 2013 | 15 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 36 | 0.030 |
Why?
|
| Program Development | 1 | 2013 | 77 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 323 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 145 | 0.030 |
Why?
|
| Telomerase | 1 | 2013 | 37 | 0.030 |
Why?
|
| Telomere | 1 | 2013 | 35 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2013 | 77 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1052 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 679 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 1433 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2011 | 15 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 35 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 190 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 238 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 81 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 1015 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 398 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 763 | 0.020 |
Why?
|
| Membrane Fusion | 1 | 2003 | 7 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2003 | 35 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2003 | 34 | 0.010 |
Why?
|
| Alanine | 1 | 2003 | 40 | 0.010 |
Why?
|
| Cysteine | 1 | 2003 | 68 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 125 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 120 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2003 | 90 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 267 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 167 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 257 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 78 | 0.010 |
Why?
|
| Temperature | 1 | 2003 | 213 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2003 | 101 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2003 | 252 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2003 | 485 | 0.010 |
Why?
|